Neuronetics has closed a $34.3 million Series F round to further commercialize its NeuroStar transcranial magnetic stimulation therapy system to treat drug-resistant major depressive disorder (MDD), as well as to fund a registration study for adolescent use of the device. NeuroStar was cleared by FDA in 2008 to treat MDD, but the company said it's just recently been gaining traction with payers.
Shares of Spectranetics, the maker of medical lasers, hit a 6-month low in heavy trading after it reported lower quarterly earnings and trimmed its forecast for the year because of increased competition from other drug-coated balloon products and its own R&D spending.
More than 55 years after pioneering the world's first color television set, Toshiba aims to become a healthcare company making medical devices. In that new realm, Toshiba still expects to be dealing with images on a machine.
Mobile health apps raised $220 million in Q1 2015. And the financial backers were ambitious. Fitness, nutrition and wellness apps accounted for only 17% of the total, while advanced apps to treat chronic conditions and illnesses took 77% of the pie.
Remember the days when Biogen's Tecfidera was trumping analyst expectation after analyst expectation? Well, they're in the past--at least for now.
AstraZeneca CEO Pascal Soriot, while fighting off the takeover attempt by Pfizer, promised that the company would hit annual revenue of $45 billion by 2023. Now he will be measured by that promise quarter by quarter and today he fell a little short.
C.R. Bard reported increased first-quarter sales as its Lutonix drug-coated balloons used to treat peripheral artery disease (PAD) in outpatients help lift the company's earnings.
Indianapolis-based Eli Lilly said Thursday that it earned 87 cents per share in the first quarter of 2015--10 cents more than analysts had expected--an achievement the company attributed largely to its $5.4 billion acquisition of Novartis Animal Health.
Shanghai Haohai Biological Technology has priced its Hong Kong initial public offering at the top end of an indicative price range of HK$48.50 to HK$59 per share to raise $305 million, better than the $263 million (HK$2.0 billion) expected, according to a source.
As of 2014, Teva is in the No. 11 spot on the list of pharma's top revenue generators. But if it gets its way and lands a deal for rival generics maker Mylan, just how much will it be moving up the charts?